Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 14 points (-0.1%) at 17,796 as of Monday, Nov. 24, 2014, 1:00 PM ET. The NYSE advances/declines ratio sits at 1,731 issues advancing vs. 1,243 declining with 202 unchanged. The Services sector currently sits up 0.7% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the sector include Jacobs Engineering Group ( JEC), down 3.2%, Ulta Salon Cosmetics & Fragrances ( ULTA), down 2.8% and Tyco International ( TYC), down 1.3%. Top gainers within the sector include Urban Outfitters ( URBN), up 4.7%, Foot Locker ( FL), up 3.5%, Hertz Global Holdings ( HTZ), up 3.5%, Gap ( GPS), up 2.6% and McKesson ( MCK), up 2.0%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Omnicare ( OCR) is one of the companies pushing the Services sector lower today. As of noon trading, Omnicare is down $2.29 (-3.2%) to $68.34 on heavy volume. Thus far, 1.9 million shares of Omnicare exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $66.28-$70.26 after having opened the day at $69.61 as compared to the previous trading day's close of $70.63. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Omnicare, Inc. operates as a healthcare services company that specializes in the management of pharmaceutical care in the United States and Canada. It operates through two segments, Long-Term Care Group and Specialty Care Group. Omnicare has a market cap of $6.9 billion and is part of the health services industry. Shares are up 17.0% year-to-date as of the close of trading on Friday. Currently there are 5 analysts that rate Omnicare a buy, no analysts rate it a sell, and 1 rates it a hold. TheStreet Ratings rates Omnicare as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Omnicare Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.